Lipidosome-protected nano-gold gene vector and preparation method thereof

Abstract

The invention provides a preparation method of a lipidosome-protected nano-gold gene vector. The preparation method comprises the following steps: dissolving dimethyldioctadecylammonium bromide and dioleoyl phosphatidyl ethanolamine into an organic solvent, removing the organic solvent, dissolving into water, and performing ultrasonic treatment to obtain a phospholipid vesicle solution, wherein the molar ratio of the dimethyldioctadecylammonium bromide to the dioleoyl phosphatidyl ethanolamine is 1:10-10:1; and mixing the phospholipid vesicle solution with a compound containing gold ions, adding a reducing agent, and reacting to obtain the lipidosome-protected nano-gold gene vector. After being compounded with genes, the lipidosome-protected nano-gold gene vector is high in transfection efficiency and high in gene release speed in a specific environment; the lipidosome-protected nano-gold gene vector is high in stability in serum and is not aggregated, and a transfection process is simplified since serum in a culture solution does not need to be removed in an in-vitro transfection process; the carrying amount of DNAs (Desoxvribose Nucleic Acids) is high, the using quantity of the DNAs is reduced, and the immunogenicity of exogenous DNAs to cytotoxicity and organisms are lowered.

Description

technical field [0001] The invention relates to the field of gene carriers, in particular to a liposome-protected nano-gold gene carrier and a method thereof. Background technique [0002] Gene therapy is an emerging gene-level treatment method, which can treat single-gene genetic diseases, polygenic diseases, cancer, infectious diseases (such as AIDS), cardiovascular diseases, etc. Gene therapy is different from conventional treatments: in general, the treatment of diseases is aimed at various symptoms caused by gene abnormalities, while gene therapy is aimed at the root of the disease - the abnormal gene itself, so it is a radical cure for the disease. A new method with great medical value. In November 1990, the NIH in the United States conducted the first clinical trial of human gene therapy, transferring the adenosine deaminase (ADA) gene to the patient's white blood cells through retroviruses. Eight months later, the ADA level in the child's body reached 25% of the no...

AI Technical Summary

Problems solved by technology

However, gold nanoparticles protected by DDAB cannot achieve the release of the target gene in the cell because of its strong interaction with the target gene, and cannot make the target gene expressed in the cell (Journal of Controlled Release2008,129,128-134)

DODAB protected gold nanoparticles can achieve the expression of the target gene, and its transfection efficiency is 4 times higher than that of DODAB, but the transfection efficiency is still low, the release of the target gene in the cell is slow, and the expression of the target gene in the cell is required. Disadvantages such as long time (Biomaterials2008, 29, 3617-3624)

Images